NeuroneticsSTIM
About: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Employees: 203
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 66 [Q1] → 67 (+1) [Q2]
1.1% less ownership
Funds ownership: 59.48% [Q1] → 58.38% (-1.1%) [Q2]
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
63% less capital invested
Capital invested by funds: $84.3M [Q1] → $31.5M (-$52.7M) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JMP Securities David Turkaly 50% 1-year accuracy 10 / 20 met price target | 209%upside $3 | Market Outperform Maintained | 14 Aug 2024 |
Canaccord Genuity William Plovanic 41% 1-year accuracy 12 / 29 met price target | 209%upside $3 | Buy Maintained | 13 Aug 2024 |
Financial journalist opinion
Based on 4 articles about STIM published over the past 30 days
